source
- Akeso reports phase 3 overall survival win for ivonescimab in advanced biliary tract cancerAkeso announced that its bispecific antibody ivonescimab combined with chemotherapy improved overall survival in a China phase 3 trial for advanced biliary tract cancer, beating the standard regime…
- Deloitte urges advanced therapy makers to adopt AI-driven digital staff to overcome operational bandwidth limitsAdvanced therapy manufacturers are confronting an operational bottleneck as their pipelines expand rapidly. More than a thousand advanced therapies are in development and the U.S. patient pool is e…